Biomoda, Inc., Maker of Early Lung Cancer Detection Test, Joins BIOCOM

Albuquerque, NM January 30, 2006 -- Biomoda, Inc. (OTCBB: BMOD) of Albuquerque, NM, (www.biomoda.com) maker of early lung cancer detection testing and other cancer diagnostic technology, announced it’s membership in BIOCOM, (www.biocom.org) a premiere life science industry association that focuses on capital formation, public policy, workforce development, and scientific discovery and development.

Biomoda trades on NASDAQ's OTC Bulletin Board: ticker symbol “BMOD”.

“BIOMCOM represents more than 500 member companies in San Diego and Southern California, an important center of the bio-technical field,” said Biomoda Vice President Leslie Robins. “Working with the association, our company strengths and enhances our potential for success by connecting with others who have the same forward-looking vision needed for technological advancement.”

Biomoda’s technology is based on a patented porphyrin application that preferentially binds to cancerous or aberrant cells extracted from lung sputum samples. Cancerous cells glow red under fluorescent light to allow detection under a microscope.

The patented technology, a non-invasive cytology based assay, is designed for cancer screening of large populations at a reasonable cost. Current diagnostic methods for lung cancer, including CT scans and X-rays, often detect the disease only at more advanced stages and are relatively expensive.

The American Cancer Society recently reported that overall rates of cancer dropped for the second straight year due in large part to early screening methods available for breast and prostate cancer, yet the rate of lung cancer is expected to climb due to the lack of early screening tests such as that developed by Biomoda and an increasing number of adult who smoke reaching the age of 60 when cancer presents itself. Lung cancer claims more lives than any other cancer. The expected 5-year survival rate for all patients combined in whom lung cancer is diagnosed is 15 percent and by contrast, the 5-year survival rate for cases detected when the disease is still localized is 50 percent. At the present time, only 16 percent of lung cancer cases are diagnosed at this early stage.

“Safe Harbor” Statement: This press release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances. Actual results may vary materially from expectations contained herein. Biomoda is under no obligation to (and expressly disclaims any such obligation) to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise